ABOUND BIO
Abound Bio specializes in generating antibody-based biological therapeutics to meet medical needs in the fields of cancer and infectious disease. Its team has developed several very large (>1011 clones each), diverse human antibody libraries in standard Fab and scFv, and unique VH domain formats. It can rapidly (days to weeks) discover novel, high affinity, binders in multiple formats, engineer them if needed to improve their drugability (developability), and convert them for multiple uses including IgGs, multispecific, CARs, fusion proteins, and antibody-drug conjugates (ADCs).
ABOUND BIO
Industry:
Biotechnology Health Care Medical Therapeutics
Address:
Pittsburgh, Pennsylvania, United States
Country:
United States
Website Url:
http://www.aboundbio.com
Status:
Active
Contact:
412-209.4544
Email Addresses:
[email protected]
Similar Organizations
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Athna Biotech
Athna Biotech specializes in developing novel nanotherapeutics for cancer.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Inspyr Therapeutics
Inspyr Therapeutics is a clinical stage company focused on novel targeted precision therapeutics for the treatment of cancer.
Gyros
Gyros is specialized in the production of automated micro-immunoassays for therapeutic protein development.
Ikaria
Ikaria develop and deliver innovative therapeutics and interventions to meet the significant needs of critically.
Immunetrics
Immunetrics, a biosimulation company, developes predictive computer models based on biological responses towards diseases and intervention.
Liebscher & Bracht
Liebscher & Bracht provides pain therapy and additional training and tools to individuals of all ages.
mAbDx
mAbDx specializes in creating novel immunodiagnostics through biomarker discovery and immunoassay development.
Physicians Toxicology
Physicians Toxicology specializes in laboratory delivering custom medication monitoring, personalized service, and education.
Precision Bioservices
Precision Bioservices offers biorepository, biobanking, and laboratory services to businesses in the life science industry.
Pregenen
Pregenen designs and engineers molecules critical to a new generation of cell-based therapies for unmet medical needs.
Sarcio
Sarcio uses regenerative cartilage cell therapy to treat patients suffering from the effects of Osteoarthritis.
Semorex Technologies
Semorex develops and commercialize innovative novel therapeutics for patients with cancer based on our proprietary technology.
Switch Biotech AG
SWITCH Biotech uses its broad knowledge and expertise of the molecular biology of the skin to develop drugs for various skin disorders.
Current Employees Featured
Official Site Inspections
http://www.aboundbio.com
- Host name: server-3-167-56-85.iad61.r.cloudfront.net
- IP address: 3.167.56.85
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Abound Bio"
Abound Bio - Galapagos
A Galapagos company. Abound Bio. Generating novel antibody-based biological therapeutics Abound Bio is a US company whose mission is to generate novel antibody-based biological …See details»
Abound Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 412-209.4544 Abound Bio specializes in generating antibody-based biological therapeutics to meet medical needs in the fields of …See details»
Abound Bio - LinkedIn
Abound Bio is a company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Abound Bio is led by ...See details»
AboundBio Company Profile 2024: Valuation, Investors ... - PitchBook
AboundBio General Information Description. Developer of immunotherapies to meet unmet medical needs in the fields of cancer and infectious disease. The company focuses on novel …See details»
AboundBio & CellPoint acquisition - Galapagos
AboundBio: towards next-gen CAR-Ts. Transaction. Bart Filius President, COO. Q&A. All. CellPoint. Tol Trimborn CEO. AboundBio. John Mellors CEO. CellPoint’s CAR-T cell-therapy is …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate
Jun 21, 2022 Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s...See details»
Galapagos acquires Abound Bio - 2021-06-21 - Crunchbase
Jun 21, 2021 Acquiring Organization: Galapagos Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 22, 2022 Galapagos NV, CellPoint and AboundBio announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 23, 2022 Through the acquisition of CellPoint and AboundBio, respectively, Galapagos gains access to an innovative, scalable, decentralized and automated point-of-care cell …See details»
Galapagos Acquires CellPoint And AboundBio - Nasdaq
Jun 22, 2022 Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model as well as a next-generation …See details»
Galapagos to buy CellPoint, AboundBio to boost access to cell …
Jun 22, 2022 Galapagos has signed agreements to acquire all outstanding shares of CellPoint and AboundBio to boost access to next-generation cell therapies, in an all-cash deal totalling …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 All cash acquisition of CellPoint for an upfront amount of €125 million, with milestone payments up to €100 million and AboundBio for $14 million Webcast presentation …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 Galapagos NV. Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s …See details»
Galapagos to acquire CellPoint and AboundBio - flanders.bio
Jun 22, 2022 In a next step, the aim is to leverage CellPoint’s platform for novel CAR-Ts originating from AboundBio’s unique fully human antibody-based library and biological drug …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s cutting-edge fully …See details»
Yufan Biotechnologies and Abound Bio Sign Multi-Year ... - BioSpace
Sep 16, 2020 About Aboundbio (https://Aboundbio.com) Abound Bio is an early stage biotechnology company whose mission is to generate novel antibody-based biological …See details»
Yufan Biotechnologies and Abound Bio Sign Multi-Year …
Sep 16, 2020 About Aboundbio (https://Aboundbio.com) Abound Bio is an early stage biotechnology company whose mission is to generate novel antibody-based biological …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 23, 2022 Galapagos NV, CellPoint and AboundBio have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly …See details»
Aboundbio Licenses Potent Human Antibodies Against the SARS …
Jul 7, 2020 About Aboundbio (https://Aboundbio.com) Aboundbio is an early stage biotechnology company whose mission is to generate novel antibody-based biological …See details»
Vor to Develop Multi-Targeted CAR-Ts with Abound Bio
Jun 10, 2021 CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a …See details»